Trofosfamide

DB12902InvestigationalSmall molecule

Trofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.

Formula / weight: C₉H₁₈Cl₃N₂O₂P · 323.58 g/mol (avg)

Resolves to

Compound

UNIIH64JRU6GJ0CAS22089-22-1ChEMBLCHEMBL462019ChEBI135381PubChem65702

Clinical / RWD

RxNorm38865ATCL01AA07

Structure

InChIKeyUMKFEPPTGMDVMI-UHFFFAOYSA-NSMILESClCCN(CCCl)P1(=O)OCCCN1CCCl

What you can answer from here — as of July 10, 2026

399Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 20 drug categories

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Trofosfamide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account